As an affiliate of Servier – and being the Center of Excellence of Antibodies – our strategic focus is to apply our streamlined and efficient antibody platform and capabilities –  in the discovery and early development of highly differentiated antibody therapeutics. Over the years, Symphogen has demonstrated our ability to deliver unique antibodies and we have advanced a number of projects from target to lead and further into clinical phases. In January 2025, the pipeline comprised 57 projects, 34 of which were in clinical development and 23 in research. Please follow this link to Servier’s development pipeline.